Race Oncology Limited

Race Oncology Limited

RAONF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$445.86M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Race Oncology LimitedRace Oncology Limited-25.4--44%--
$-1.74

Current Fair Value

166.9% downside

Overvalued by 166.9% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$445.86 Million
Enterprise Value$411.57 Million
Earnings per Share$-0.03
Beta1.91
Outstanding Shares171,483,903

Return

Return on Equity-43.56%ROE
Return on Assets-41.68%
Return on Invested Capital-47.01%

Valuation & Multiples

P/E Ratio-25.44P/E Ratio
PEG-79.17PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue68.1
Enterprise Value to EBIT-24
Enterprise Value to Net Income-26
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Race Oncology Limited

5 employees
CEO: Daniel Tillett

Headquartered in Sydney, Australia, Race Oncology Limited is a precision oncology company focused on advancing its lead therapeutic, Zantrene. This potent small molecule compound acts as an inhibitor of the fatso/fat mass and obesity ass...